Interesting panel on SBIR rules

This report comes from from an interesting panel on the SBIR rule changes at the 2005 Mid-Altlantic BIO, presented by Douglas Duncan (Montgomery County County Executive), Michael Rosenwald (Washington Post biotech reporter), Douglas Doerfler (President & CEO, MaxCyte), Gerald McGarrity (President & CEO, Intronn), Barry Michael (Michael Consulting), Maciek Sasinowski (CEO, INCOGEN), and Mary Woolley (President & CEO, Research! America)

Briefly, recent rule changes disqualify small companies that are more than 50% held by entities that do not qualify as small companies. The impact of this rule is that most venture-backed organizations are no longer eligible for SBIR funding.

Some of the opinions that arose from the discussion are:

From Yali Friedman, Ph.D.,

Full Story: http://biotech.about.com/b/a/213774.htm